ArticlePhysical and engineering sciences in medicine2026
Monte Carlo-based dosimetric comparison of CCA and CCB radioactive eye plaques for uveal melanoma.
Article in Physical and engineering sciences in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study conducted a comprehensive dosimetric analysis of three beta-emitting radionuclides ⁹⁰Sr, ¹⁰⁶Ru, and ¹⁴²Pr embedded in two ophthalmic plaque models, the Concave Circular Applicator (CCA) and Concave Circular Brachytherapy (CCB), with different backing materials (gold, silver, and gadolinium). Using Geant4-based Monte Carlo simulations, dose distributions within ocular structures were analyzed to optimize tumor coverage while minimizing radiation exposure to critical tissues. Validation with EBT3 radiochromic films demonstrated dose discrepancies below 5%, confirming the accuracy of the model. The results showed that ¹⁴²Pr combined with a gadolinium-backed CCB plaque achieved the most favorable therapeutic ratio, delivering a high tumor dose while reducing radiation to the lens and optic nerve. Gadolinium exhibited an advantageous balance between backscatter enhancement and moderate bremsstrahlung emission compared to gold and silver. These findings highlight the potential of ¹⁴²Pr-Gd-CCB configurations for personalized ocular brachytherapy, particularly for small to medium uveal melanomas. Future research should integrate patient-specific anatomical models to further optimize treatment planning and clinical translation.
Indexed as
Identifiers
42090103What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.